Triple regression in MI patients with alirocumab linked to low LDL C and MACE

Key findings from this study are:

· 84 patients, constituting 31.7%, showed triple regression (40.8% in the alirocumab vs 23.0% in the placebo group).

· Low-density lipoprotein cholesterol levels were lower in those with vs without triple regression on-treatment. The between-group difference was −27.1 mg/dL.

· Triple regression was independently predicted by treament with alirocumab and a higher baseline maximum lipid core burden index within 4 mm with OR of 2.83 and 1.03, respectively.

· The composite clinical endpoint of death, myocardial infarction, and ischemia-driven revascularization occurred less frequently in patients with vs without triple regression (8.3% vs 18.2%)

This study demonstrated that among patients with acute myocardial infarction receiving high-intensity lipid-lowering therapy, one-third experienced a triple regression associated with alirocumab treatment, higher baseline lipid content, and reduced cardiovascular events.

As acknowledged, the study was funded by Bern University Hospital.

Reference:

Biccirè, F. G. et al. Concomitant coronary atheroma regression and stabilization in response to Lipid-Lowering therapy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2023.08.019